MREO Research and Charts

MREO - Mereo BioPharma Group PLC ADR (Healthcare: Biotechnology)

Projected Earnings Date: 2024-07-02 (Delayed quote data 2025-01-03)

Last 3.73	Change ⇑ +0.31 (+9.06%)	Volume 1,019,296
	Open 3.45	High 3.76	Low 3.42

8EMA (Daily) 3.58	40EMA (Daily) 3.70	50EMA (Daily) 3.75	STO (Daily) 58.521	MACD Hist (Daily) 0.044
8EMA (Weekly) 3.745	40EMA (Weekly) 3.71	50EMA (Weekly) 3.57	STO (Weekly) 32.942	MACD Hist (Weekly) -0.176


Company Profile
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.